RBDCOV Project

Notification of first patient treated in Variants' clinical trial

D4.4

PROJECT CO-FUNDED BY EUROPEAN COMMISSION WITHIN THE SEVENTH

DISSEMINATION LEVEL

PU	Public	☒
C-UE	EU CONFIDENTIAL under the Commission Decision No2015/444	☐
R-UE	EU RESTRICTED under the Commission Decision No2015/444	☐
SE	Sensitive, limited under the conditions of the Grant Agreement	☐

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement Nº 101046118

1. Overview

Deliverable 4.4 notifies the Inclusion of the first patient vaccinated In the clinical trial described In WP4. WP4 includes a multicentre, open-label, single arm, Phase III safety and immunogenicity study of the RBDCOV SARS-CoV-2 – Variants vaccine in adults from 18 years of age with stable immunosuppressive conditions (i.e HIV infection with <400 CD4+ T cells within 6 months preceding inclusion in the trial, primary immunodeficiencies, chronic kidney disease on dialysis program, kidney transplant and patients with chronic auto-immune disease (AID) on biologic immunosuppressive therapies during at least 14 days within the last 6 months) . The aim of the trial is to evaluate a safe and effective vaccine for the prevention of COVID-19 given as a booster vaccination in special populations to induce higher and more durable immune response, specially towards new and future viral variants.

The first patient was vaccinated May, 12th 2022.

This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101046118